3D Microtissue Formation from Stem Cell Hepatocytes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro models for liver toxicity, particularly those using cancer-derived cell lines and primary human hepatocytes, are limited in their predictive ability due to functional liabilities and the inability to maintain liver-specific functions in two-dimensional culture, necessitating the development of more stable and predictive three-dimensional microtissue models from pluripotent stem cell-derived hepatocytes.
Innovation Solution
A method for producing three-dimensional microtissue from pluripotent stem cell-derived hepatocytes by culturing them in the presence of extracellular matrix proteins in a cell non-adhesive environment, which enhances cell-to-cell adhesion and maintains liver-specific functions, including drug-induced cytochrome P450 activity, and allows for the tuning of microtissue size and viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary human hepatocytes are cultured in two-dimensional static culture, then they can be obtained from biopsy or surgical resection, but they rapidly decline in cytochrome P450 function and require extracellular matrix protein overlay to survive
Solution Approach 1:
The patent transitions from two-dimensional static culture to three-dimensional microtissue culture. This dimensional change enables cells to self-assemble into spheroidal structures that better replicate in vivo liver architecture, maintaining cytochrome P450 function and other liver-specific activities over extended culture periods without requiring extracellular matrix overlays.
Solution Approach 2:
The microtissue system enables hepatocytes to self-organize and self-maintain their functional properties through cell-cell interactions and spontaneous formation of 3D structures. The cells autonomously regulate their metabolic functions and structural organization without external support matrices, preserving liver-specific functions naturally.
2Productivity
If cancer-derived cell lines are used for hepatotoxicity assessment, then unlimited cell supply is available, but they are limited in drug metabolizing functions
Solution Approach 1:
The patent employs pluripotent stem cells as a starting material that can be indefinitely expanded (maintaining productivity) and then differentiated into functional hepatocytes (gaining reliability). The differentiation process transforms the cellular parameters from undifferentiated state to a state with full liver-specific metabolic functions, including cytochrome P450 activity, while maintaining unlimited supply capability through stem cell self-renewal.
3Adaptability or versatility
If primary hepatocytes are removed from in vivo setting, then they can be cultured in vitro, but they do not adapt well to tissue culture environment and rapidly decline in function
Solution Approach 1:
By culturing cells in three-dimensional microtissues rather than two-dimensional monolayers, the patent creates a culture environment that better mimics the in vivo tissue architecture. This 3D configuration allows primary hepatocytes to maintain their functional properties and adapt to culture conditions without the rapid functional decline observed in traditional 2D cultures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces stable and functional three-dimensional microtissue with increased liver-specific function and viability, improving the predictive power for drug-induced liver toxicity and enabling extended culture periods, thus addressing the limitations of existing two-dimensional models.
Implementation Method 1
culturing them in the presence of extracellular matrix proteins in a cell non-adhesive environment, which enhances cell-to-cell adhesion
Data Source
Figure 1
Figure 2A~3A
Figure 3B~3D
AI summary
Provided herein are methods of producing three-dimensional (3-D) microtissue from a starting cell suspension of pluripotent stem cell (PSC)-derived hepatocytes. Such a method may comprise supplementing the cell suspension with cell adhesion-promoting components and culturing the PSC-derived hepatocytes on a non-adhesive surface to produce the microtissue.